Eli Lilly Ordered to Pay Teva Approximately $176.5 Million in Damages

November 11, 2022

A federal jury in Massachusetts has decided that Eli Lilly must pay Teva Pharmaceuticals approximately $176.5 million in damages over infringement of three patents covering Teva’s migraine treatment Ajovy (fremanezumab-vfrm).

Teva filed a complaint in a U.S. District Court in Massachusetts in September 2018 accusing Lilly of violating the patents with Emgality (galcanezumab-gnlm), which is FDA-approved for the preventive treatment of migraine in adults.

Teva filed a second lawsuit concerning patent infringement by Emgality in June 2021 which is ongoing.

View today's stories